X0306 4 2020-02-03 0 0001701541 Black Diamond Therapeutics, Inc. BDTX 0001613867 Behbahani Ali 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093 1 0 0 0 Common Stock 2020-02-03 4 C 0 2176957 A 2176957 I See Note 2 Common Stock 2020-02-03 4 C 0 471800 A 2648757 I See Note 2 Common Stock 2020-02-03 4 P 0 800000 19.00 A 3448757 I See Note 2 Series B Preferred Stock 2020-02-03 4 C 0 6565290 D Common Stock 2176957 0 I See Note 2 Series C Preferred Stock 2020-02-03 4 C 0 1422862 D Common Stock 471800 0 I See Note 2 Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date. The Reporting Person is a manager of NEA 16 GP, LLC, ("NEA 16 GP") which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by NEA 16 in which the Reporting Person has no pecuniary interest. Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. /s/ Sasha Keough, attorney-in-fact 2020-02-05